Risk factors for prolonged dexamethasone intravitreal implan
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study evaluated the effects of dexamethasone intravitreal implant on treatment-naive branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment.

29 patients (mean age: 58.64 ± 13.3 years) were included. The patient's demographics, medical history, best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded. Risk factors for repeated treatment were identified using a Cox proportional hazard model and logistic regression.

Results:
--44.8% received only one injection, while 55.2% received two or more.

--The mean initial CRT was 457.8 ± 167.1 microm; the peak CRT and final CRT improved significantly to 248.9 ± 57.9 microm and 329.2 ± 115.1 microm, respectively.

--The peak BCVA improvement and final improvement were 29.5 ± 23.5 approximate ETDRS letters and 19.8 ± 24.4 letters, respectively, with 62.1% of patients improving by more than 15 letters.

--Older age, higher initial CRT, and diabetes were the risk factors for multiple injections.

In conclusion, Dexamethasone intravitreal implant improves peak CRT and BCVA significantly, while older age, higher initial CRT, and diabetes are risk factors for frequent injections.

Source: https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-021-01904-8
1 share
Like
Comment
Share